Protagenic Therapeutics, Inc.\new Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for the quarter ending 2022-06-30 was $40.02K, a 96.21% decline year-over-year.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for the quarter ending 2022-03-31 was $54.97K.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $220.88K.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for the quarter ending 2021-06-30 was $1.05M.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for fiscal 2023 was $520.87K, a 448.37% increase from fiscal 2022.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for fiscal 2022 was $94.98K, a 94.04% decline from fiscal 2021.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for fiscal 2021 was $1.59M.
- Protagenic Therapeutics, Inc.\new stock issued during period, value, conversion of convertible securities for fiscal 2016 was $75.27K.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2023-12-31 | $520.87K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $94.98K 10-K/A · filed 2024-05-14 | |
| 2022-06-30 | $40.02K 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $54.97K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $1.59M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $220.88K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.05M 10-Q · filed 2022-11-14 | |
| 2020-03-31 | $1.05M 10-Q · filed 2021-08-16 | |
| 2016-12-31 | $75.27K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |